Interferon-gamma and host antimicrobial defense: current and future clinical applications

Area of Science:

• Immunology
• Infectious Diseases
• Biotechnology

Background:

• Interferon-gamma (IFN-gamma), a T-cell lymphokine, activates macrophages and shows potential against nonviral pathogens.
• Research has expanded on IFN-gamma's efficacy in treating various nonviral infections.
• Clinical trials have investigated IFN-gamma for patients at risk or with active infections.

Purpose of the Study:

• To review the current status and potential of interferon-gamma (IFN-gamma) as a host defense-enhancing antimicrobial agent.
• To evaluate the clinical effectiveness of IFN-gamma in treating nonviral infections.
• To identify areas where IFN-gamma's therapeutic potential remains unexplored.

Main Methods:

• Literature review of experimental data and clinical trial results.
• Analysis of IFN-gamma's efficacy in treating specific nonviral infections.
• Assessment of IFN-gamma's approved uses and adjunctive therapeutic roles.

Main Results:

• IFN-gamma is approved for prophylaxis in chronic granulomatous disease.
• It shows effectiveness as adjunctive therapy for visceral leishmaniasis and other intracellular infections.
• Potential benefits observed in cutaneous leishmaniasis, Mycobacterium avium complex, and leprosy.

Conclusions:

• IFN-gamma is a promising cytokine for enhancing host defense against nonviral pathogens.
• Its therapeutic potential is established in certain infections but remains largely unexplored in others.
• Further research is needed for tuberculosis, fungal, bacterial, and AIDS-related opportunistic infections.